Comprehensive comparison of global coagulation assays to differentiate lupus anticoagulant from acquired hemophilia A in patients with prolonged APTT

Int J Hematol. 2023 Nov;118(5):577-588. doi: 10.1007/s12185-023-03659-y. Epub 2023 Sep 26.

Abstract

There is no established method for differentiating acquired hemophilia A (AHA) from lupus anticoagulant (LA) positivity because both present with prolonged activated partial thromboplastin time. We compared various parameters of rotational thromboelastometry (ROTEM), thrombin generation assay (TGA), and clot waveform analysis (CWA) in patients with AHA (n = 10) and LA (n = 44). Compared with AHA, possible (n = 12) and definite (n = 32) LA showed significantly shorter clotting time (CT) in NATEM mode of ROTEM (> 3600 vs. 501/533). In TGA, peak height was significantly lower in AHA (16 vs. 242/174 nM). In CWA, CT was significantly longer (81 vs. 36/41 s) and Ad|min1| was lower (2.1 vs. 8.7/6.7) in AHA. Notably, CT by NATEM and peak height in TGA completely discriminated between AHA and LA, whereas Ad|min1| did not discriminate between them in 4 cases of AHA and 1 of LA. Comparison of 3 patients with both AHA and LA against a patient with only LA and markedly low FVIII activity (3.5%) showed that both CT by NATEM and peak height of TGA precisely classified the former 3 cases as AHA and the latter 1 case as LA, whereas Ad|min1| classified all 4 cases as AHA. ROTEM and TGA can comparably distinguish between AHA and LA.

Keywords: Acquired hemophilia; Clot waveform analysis; Lupus anticoagulant; NATEM mode in ROTEM; Thrombin generation assay.

MeSH terms

  • Antiphospholipid Syndrome*
  • Blood Coagulation Tests / methods
  • Hemophilia A* / complications
  • Hemophilia A* / diagnosis
  • Humans
  • Lupus Coagulation Inhibitor
  • Partial Thromboplastin Time
  • Thrombin

Substances

  • Lupus Coagulation Inhibitor
  • Thrombin

Supplementary concepts

  • Factor 8 deficiency, acquired

Grants and funding